Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.

ABSTRACT:

Objective

To explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice.

Summary

In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23andMe (Mountain View, CA), to return select pharmacogenomic test results to their customers. Given the community pharmacist's high accessibility to the public and in-depth knowledge of pharmacology, and the availability of direct-to-consumer genetic testing kits at pharmacies, it is likely that patients will present their pharmacogenomic test results to their pharmacists and expect them to incorporate those results into their care. It is important, therefore, that community pharmacists are aware of the clinical implications of thes

SUBMITTER: Gammal RS 

PROVIDER: S-EPMC7229642 | biostudies-literature | 2019 Sep - Oct

REPOSITORIES: biostudies-literature